

Appl. No. 09/854,883
Amdt dated November 26, 2003
Reply to Office Action of June 27, 2003

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (Currently Amended): A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule (SEQ ID NO: 243) encoding human PTP1B, wherein said compound specifically hybridizes with and inhibits the expression of human PTP1B.

Claim 2 (Original): The compound of claim 1 which is an antisense oligonucleotide.

Claim 3 (Cancelled).

Claim 4 (Original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Claim 5 (Original): The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Claim 6 (Original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Claim 7 (Original): The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

Appl. No. 09/854,883
Amdt dated November 26, 2003
Reply to Office Action of June 27, 2003

Claim 8(Original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 9(Original): The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

Claim 10(Original): The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Claim 11(Original): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 12(Original): The composition of claim 11 further comprising a colloidal dispersion system.

Claim 13(Original): The composition of claim 11 wherein the compound is an antisense oligonucleotide.

Claim 14 (Currently Amended): A compound 8 to 50 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of the nucleic acid sequence SEQ ID NO: 243, wherein said hybridization at said 8-nucleobase portion modulates decreases expression of PTP1B.

Claim 15(Original): A method of inhibiting the expression of PTP1B in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of PTP1B is inhibited.

Appl. No. 09/854,883
Amdt dated November 26, 2003
Reply to Office Action of June 27, 2003

Claim 16(Original): The method of claim 15 wherein the cells or tissues are human cells or tissues.

Claim 17(Original): The method of claim 15 wherein the cells or tissues are rodent cells or tissues.

Claim 18(Original): The method of claim 17 wherein the rodent cells or tissues are mouse cells or tissues.

Claim 19(Original): The method of claim 17 wherein the rodent cells or tissues are rat cells or tissues.

Claim 20(Original): The method of claim 15 wherein the cells or tissues are liver, kidney or adipose cells or tissues.

Claim 21(Cancelled).

Claim 22(Previously Presented): The method of claim 30 wherein the animal is a human.

Claims 23 and 24 (Cancelled)

Claim 25(Previously Presented): The method of claim 32, wherein said animal has Type 2 diabetes.

Claim 26(Previously Presented): The method of claim 29 wherein said animal is obese.

Claims 27 and 28. (Cancelled)

Appl. No. 09/854,883
Amdt dated November 26, 2003
Reply to Office Action of June 27, 2003

Claim 29 (Currently Amended): A method of decreasing blood glucose levels in an animal comprising administering to said animal the a compound of claim 1 8 to 50 nucleobases in length targeted to a nucleic acid molecule (SEQ ID NO: 243) encoding PTP1B, wherein said compound specifically hybridizes with and inhibits the expression of PTP1B.

Claim 30 (Original): The method of claim 29 wherein the animal is a human or a rodent.

Claim 31 (Original): The method of claim 29 wherein the blood glucose levels are plasma glucose levels or serum glucose levels.

Claim 32 (Original): The method of claim 29 wherein the animal is a diabetic animal.

Claims 33 - 36 (Cancelled).

Claim 37 (Currently Amended): The A method of claim 44 wherein the preventing or delaying the onset of an increase in blood glucose levels in an animal has comprising administering to said animal with Type 2 diabetes a compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule (SEQ ID NO: 243) encoding PTP1B, wherein said compound specifically hybridizes with and inhibits the expression of PTP1B.

Claim 38 (Currently Amended): The A method of claim 41 wherein said preventing or delaying the onset of an increase in blood glucose levels in an obese animal is obese comprising administering to said animal a compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule (SEQ ID NO: 243)

Appl. No. 09/854,883
Amdt dated November 26, 2003
Reply to Office Action of June 27, 2003

encoding PTP1B, wherein said compound specifically hybridizes with and inhibits the expression of PTP1B.

Claims 39 - 40 (Cancelled).

Claim 41 (Currently Amended): A method of ~~preventing or~~ delaying the onset of an increase in blood glucose levels in an animal comprising administering to said animal the a compound of claim 1 8 to 50 nucleobases in length targeted to a nucleic acid molecule (SEQ ID NO: 243) encoding PTP1B, wherein said compound specifically hybridizes with and inhibits the expression of PTP1B.

Claim 42 (Original): The method of claim 41 wherein the animal is a human or a rodent.

Claim 43 (Original): The method of claim 41 wherein the blood glucose levels are plasma glucose levels or serum glucose levels.

Claim 44 (Original): The method of claim 41 wherein the animal is a diabetic animal.

Claim 45 (Currently Amended): A method of lowering plasma insulin levels in an animal comprising administering to said animal the a compound of claim 1 8 to 50 nucleobases in length targeted to a nucleic acid molecule (SEQ ID NO: 243) encoding PTP1B, wherein said compound specifically hybridizes with and inhibits the expression of PTP1B.

Claim 46 (Previously Presented): The method of claim 45 wherein said animal is a non-human primate or human.

Appl. No. 09/854,883
Amdt dated November 26, 2003
Reply to Office Action of June 27, 2003

Claim 47 (Currently Amended): A method of increasing insulin sensitivity in an animal comprising administering to said animal the a compound of claim 1 8 to 50 nucleobases in length targeted to a nucleic acid molecule (SEQ ID NO: 243) encoding PTP1B, wherein said compound specifically hybridizes with and inhibits the expression of PTP1B.

Claim 48 (New): The method of claim 15, wherein said cells or tissues are monkey cells or tissues.

Claim 49 (Currently Amended): A method of treating, or delaying the onset of, Type 2 diabetes in an animal comprising administering to said animal the a compound of claim 1 8 to 50 nucleobases in length targeted to a nucleic acid molecule (SEQ ID NO: 243) encoding PTP1B, wherein said compound specifically hybridizes with and inhibits the expression of PTP1B.

Claim 50 (New): The compound according to claim 1, wherein said inhibition is at least 50% inhibition of human PTP1B expression.